Screening for Term Preeclampsia at 35 to 37 Weeks of Gestation: A Single-Center Experience.
Options
BORIS DOI
Publisher DOI
PubMed ID
40763716
Description
Introduction
Prevention of preeclampsia has short- and long-term benefits for maternal health. Recent data suggest that combined screening at 35-37 weeks of gestation with anamnestic risk factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), and angiogenic profile (sFlt-1/PlGF) detects up to 80% of all tPE. The aim of this retrospective analysis was to test the performance of third-trimester screening for tPE in a single center in Switzerland.Methods
Singleton pregnancies with complete background risk assessments, MAP, and, if available, UtA-PI and sFlt-1/PlGF from 2018 to 2023 were included and risks were calculated on the FMF London website.Results
1,121 pregnancies, including 22 (2.0%) with tPE, were analyzed. Median MAP-MoM [IQR] in tPE was 1.08 [1.00-1.14], compared to 0.98 [0.92-1.04] in controls (p < 0.0001). Median UtA-PI-MoM [IQR] in tPE was 1.04 [0.85-1.27] versus 0.99 [0.82-1.15] (p = 0.56). No sFlt-1/PlGF recordings in tPE were available for analysis. The detection rate in combined screening was 15/22 (68.2%) compared to screening by anamnestic risk factors only of 9/22 (40.9%).Conclusion
This analysis shows that combined screening at 35-37 weeks of gestation including anamnestic risk factors and MAP performs better than screening by anamnestic risk factors alone. These results should further be verified in a prospective trial including all markers.
Prevention of preeclampsia has short- and long-term benefits for maternal health. Recent data suggest that combined screening at 35-37 weeks of gestation with anamnestic risk factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), and angiogenic profile (sFlt-1/PlGF) detects up to 80% of all tPE. The aim of this retrospective analysis was to test the performance of third-trimester screening for tPE in a single center in Switzerland.Methods
Singleton pregnancies with complete background risk assessments, MAP, and, if available, UtA-PI and sFlt-1/PlGF from 2018 to 2023 were included and risks were calculated on the FMF London website.Results
1,121 pregnancies, including 22 (2.0%) with tPE, were analyzed. Median MAP-MoM [IQR] in tPE was 1.08 [1.00-1.14], compared to 0.98 [0.92-1.04] in controls (p < 0.0001). Median UtA-PI-MoM [IQR] in tPE was 1.04 [0.85-1.27] versus 0.99 [0.82-1.15] (p = 0.56). No sFlt-1/PlGF recordings in tPE were available for analysis. The detection rate in combined screening was 15/22 (68.2%) compared to screening by anamnestic risk factors only of 9/22 (40.9%).Conclusion
This analysis shows that combined screening at 35-37 weeks of gestation including anamnestic risk factors and MAP performs better than screening by anamnestic risk factors alone. These results should further be verified in a prospective trial including all markers.
Date of Publication
2025-08-05
Publication Type
Article
Subject(s)
Keyword(s)
Preeclampsia
•
Screening
•
Third trimester
Language(s)
en
Contributor(s)
Diethelm, Selina Manuela | |
Musik, Thabea | |
Monod, Cécile | |
Hildebrandt, Lysann | |
Lapaire, Olav | |
Manegold-Brauer, Gwendolin |
Additional Credits
Series
Fetal Diagnosis and Therapy
Publisher
Karger Publishers
ISSN
1421-9964
1015-3837
Access(Rights)
open.access